NASDAQ: RGEN

Repligen (RGEN) Stock Analysis & Forecast

Nov 13 close

$167.79+1.27 (+0.8%)

Gekko Brief

AI summaryNov 9 close

Repligen's record third quarter headlines the week, with revenue of $209 million reflecting 12.5% organic growth and 170 basis points of adjusted operating margin expansion year-over-year, alongside the closed BioLife acquisition expected to add $24 million in fourth-quarter revenue. Investors also weighed a Q3 net loss of $38.43 million, driven by $41.24 million in intangible asset impairment charges and new convertible senior notes. RBC Capital Markets reiterated an Outperform rating, citing confidence in filtration business growth returning to historical rates next year, while Stifel maintained a Buy rating with a $207 price target, pointing to upside from the Biolife deal and margin synergies. Repligen's CEO is also set to join an analyst discussion in London on 18 November.

The stock closed at $178.94, up 3.1%, sitting above both its 50-day average of $177.40 and 200-day average of $145.08, with the 50-day above the 200-day. The GekkoIndex reads 56.4, placing it in the Neutral zone, down 3.8 over five days. Price sits 8% above Gekko Fair Value of $165.70.

Over the next 20 trading days, the next earnings date falls on 23 February 2027, outside this window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, though one billionaire holder and two trailblazer holders are noted. Seasonality over five years shows an average 20-day return of 1.3%, rising in 2 of those years. Consensus among 9 analysts stands at 8 buy, 1 hold, with a target of $203.45.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Repligen price vs fair value

$167.79$165.83Nov ’25May ’26Nov ’26
Close $167.79200-day averageGekko Fair Value $165.83

Repligen quick facts

Market cap
$10.73B
P/E ratio
—
Forward P/E
62.1
EPS, TTM
−$0.21
Revenue, TTM
$805.6M
Profit margin
-1.5%
Dividend yield
—
Beta
1.12
Volume
510,106 avg 1.26M
1-year return
+6.2%
Typical daily move
±5.5%
Typical 20-day move
±7.5%
50-day average
$177.15
200-day average
$145.27
Next earnings
Feb 23 before open
Shares outstanding
63.92M
52-week range
$100.99$198.87

Repligen swing-trade checklist

Repligen scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $167.79 sits between the 50-day ($177.15) and 200-day ($145.27) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    61, Accumulation

    Reading 61 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuemixed

    1.2% above

    Price is within 5% of Gekko Fair Value (1.2% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +1.6% on average

    From this point in the calendar, the next 20 trading days averaged +1.6% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Repligen stock chart and price history

Repligen closed at $167.79 on Nov 13, 2026, +6.2% over the past year, inside a 52-week range of $100.99 to $198.87.

Close50-day average200-day averageVolume
Repligen share price, past year, with 50-day and 200-day moving averages and volume$100$120$140$160$180$200DecJan 2026FebMarAprMayJunJulAugSepOctNov167.79

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−8.9%
3 months
−0.7%
6 months
+63.1%
1 year
+6.2%
The full RGEN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RGEN in Gekko

Follow Repligen through every session

Put RGEN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track RGEN in GekkoFree for 7 days. No credit card required.

About Repligen

Repligen builds tools and equipment that support the manufacture of biologic drugs, covering several steps of that process. Among its best known items are Protein A ligands used inside affinity chromatography resins, along with its OPUS pre-packed columns for purifying biologics and smaller OPUS formats used for screening, viral clearance testing and scaled-down purification work. The company also makes ELISA kits, CaptivA-branded resins, and a wide range of filtration gear including XCell Alternating Tangential Flow units, TangenX flat sheet cassettes, KrosFlo tangential flow and depth filtration systems, Spectra/Por dialysis products, SpectraFlo dialysis units, ProConnex single-use hollow fibers, and spectroscopy instruments sold as SoloVPE, FlowVPE and FlowVPX.

Its customer base spans life sciences groups, biopharma and diagnostics firms, academic and industry researchers, and contract manufacturers, with sales reaching organizations in North America, Europe, Asia Pacific and elsewhere. Repligen also teams up with outside firms, among them Navigo Proteins GmbH, to jointly develop affinity ligand technology.

The company traces back to 1981 and runs its headquarters out of Waltham, Massachusetts. Its stock trades on the NASDAQ under the ticker RGEN.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
repligen.com

Repligen GekkoIndex: the smart money zone

Repligen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61, in the Accumulation zone, up 2 points over five sessions.

010061Accumulation

Up 2 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying48−0.6%−3.0%−3.0%−2.7%
Accumulation (current zone)222+1.3%+2.1%+2.6%+2.5%
Neutral396−0.3%−0.1%0.0%+1.6%
Distribution35+0.1%−0.7%−2.6%−8.9%
Selling1Too few readings yet

Average RGEN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the RGEN price, zone by zone.Track RGEN in Gekko

Is Repligen stock overvalued? Gekko Fair Value

Repligen trades 1.2% above Gekko Fair Value of $165.83, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Repligen shares are worth, recalculated every trading day.

$165.83

Gekko Fair Value, Nov 14, 2026

1.2% above fair value · About fair value

At the end of Aug 2026 the price was 3.9% above the estimate.

Gekko Fair ValueShare price, month end
$166$168Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open RGEN in Gekko

Repligen insider and Congress trading

No open-market insider purchases were filed for Repligen, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for RGEN in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every RGEN insider filing, plotted on the chart in Gekko.Open RGEN in Gekko

Congress trades last 90 days

No trades in RGEN were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for RGEN, plotted on the chart in Gekko.Open RGEN in Gekko

Buybacks

Repligen has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$1.07M
As a share of market cap
0.01%

From company filings.

Hedge funds and billionaires quarter ended Sep 30

2of the funds Gekko tracks hold RGEN.

1added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Repligen earnings: next date and track record

Repligen reports on Feb 23, 2027, before the open (100 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±4.9%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+5.5%Feb ’25−3.9%Apr ’25+2.7%Jul ’25−7.8%Oct ’25−2.4%Feb ’26+6.4%May ’26+7.8%Jul ’26+2.5%Oct ’26

Last earnings call, Oct 27, 2026 AI summary

What they said
Repligen reported a record Q3 2026 revenue of $209 million, representing 12.5% organic growth and 170 basis points of adjusted operating margin expansion year-over-year. Growth was driven by proteins, chromatography, consumables (20% growth), and services (>20% growth). The company closed the BioLife acquisition in Q4, expected to contribute $24 million in revenue for the partial period, with BioLife's 2026 pro forma revenue tracking at ~$114 million.
Guidance
Full year 2026 organic growth guidance narrowed to 12-13%, with BioLife contributing ~$24 million in Q4. Management increased full year guidance incorporating the acquisition and expressed confidence in delivering the BioLife deal model for 2027 and beyond.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 27, 2026$0.53
est $0.46
+14.5%$209.3M
est $206.7M
+1.3%+2.5%
Jul 28, 2026$0.54
est $0.45
+20.8%$204.1M
est $201.6M
+1.3%+7.8%
May 5, 2026$0.48
est $0.39
+23.1%$194.3M
est $192.1M
+1.1%+6.4%
Feb 24, 2026$0.49
est $0.44
+11.5%$197.9M
est $192.9M
+2.6%−2.4%
Oct 28, 2025$0.46
est $0.42
+9.5%$188.8M
est $192.2M
−1.8%−7.8%
Jul 29, 2025$0.37
est $0.40
−7.5%$182.4M
est $181.8M
+0.3%+2.7%
Apr 29, 2025$0.39
est $0.35
+11.4%$169.2M
est $173.6M
−2.5%−3.9%
Feb 20, 2025$0.44
est $0.42
+5.0%$167.5M
est $164.1M
+2.1%+5.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Repligen stock forecast and analyst price targets

Analysts’ average 12-month price target for Repligen is $203.21, +21.1% from the last close, from 9 firms rating the stock in the last 90 days.

$203.21consensus 12-month target, +21.1% from the last close
Low $180High $235
Buy8
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 11Stifel NicolausBuy, maintained$207+23.4%
Nov 2Stifel NicolausBuy, maintained$207+23.4%
Nov 1RBC CapitalBuy, maintained$200+19.2%
Oct 29J.P. MorganBuy, maintained$205+22.2%
Oct 28Canaccord GenuityHold, reiterated$180+7.3%
+2.6%average 20-day move after past Accumulation readings
+1.6%average move over the next 20 trading days in the last 5 years
±5.5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Repligen seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Repligen averaged +1.6% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−3.4%2021−11.3%2022+13.7%2023+9.8%2024+5.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.5%3 of 5
Next 10 trading days+1.1%3 of 5
Next 15 trading days−3.0%2 of 5
Next 20 trading days+1.6%3 of 5
Next 30 trading days+1.4%2 of 5

For scale, RGEN’s typical 20-trading-day move in either direction is about 7.5%.

Repligen market cap and key statistics

Repligen’s market cap is $10.73B and revenue of $805.6M over the last twelve months.

Valuation

Market cap
$10.73B
Forward P/E
62.1
EPS, TTM
−$0.21
Gekko Fair Value
$165.83

Trading

Volume
510,106
Avg volume, 20 days
1.26M
52-week high
$198.87
52-week low
$100.99
Shares outstanding
63.92M

Financials

Revenue, TTM
$805.6M
Profit margin
-1.5%
Return on equity
-0.6%
Quarterly earnings growth, YoY
−65.9%

Risk and income

Beta
1.12
Typical daily move
±5.5%
Typical 20-day move
±7.5%

Repligen stock news this week

2 headlines about Repligen from the past week, newest first, each linking to the publisher.

Repligen peers

Repligen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Repligen stock FAQ

What is Repligen’s market cap?

Repligen’s market cap is $10.73B at the Nov 13, 2026 close of $167.79, with 63.92M shares outstanding.

What is the Repligen stock forecast?

The consensus analyst 12-month price target for Repligen is $203.21, +21.1% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Repligen stock overvalued or undervalued?

On Gekko’s estimate Repligen is about fair value: the Nov 13, 2026 close of $167.79 is 1.2% above Gekko Fair Value of $165.83. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Repligen report earnings next?

Repligen is expected to report on Feb 23, 2027, before the market opens (100 days away). Analysts expect earnings of $0.54 per share on revenue of $241.0M. Repligen beat the earnings estimate in 7 of its last 8 reports, moving 4.9% on average across the report.

What is Repligen’s 52-week high and low?

Repligen’s 52-week high is $198.87 and its 52-week low is $100.99; it closed at $167.79 on Nov 13, 2026, +6.2% over the past year. Over the last five years the shares peaked at $300.23 on Nov 26, 2021.

Is Repligen stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, earnings risk and seasonality), 2 as mixed (trend and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Repligen the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.